Lawrence Kenyon
Director of Finance/CFO chez OUTLOOK THERAPEUTICS, INC.
Fortune : 11 295 $ au 31/03/2024
Profil
Lawrence A.
Kenyon is currently the CFO, Secretary, Treasurer & Director at Outlook Therapeutics, Inc. He previously held positions as President, CEO, CFO & Secretary at Tamir Biotechnology, Inc. from 2011 to 2013, Director at Tamir Biotechnology, Inc. in 2007, Chief Financial Officer & Executive Vice President at Endo Generics Holdings, Inc. from 2008 to 2010, Chief Financial Officer, Secretary & EVP at NeoPharm, Inc. from 2000 to 2006, Chief Financial Officer at Par Pharmaceutical, Inc. from 2008 to 2010, and Chief Operating & Financial Officer at Arno Therapeutics, Inc. from 2014 to 2015.
Mr. Kenyon obtained his undergraduate degree from the University of Wisconsin in 1987.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 20/03/2024 | 946 ( 0,00% ) | 11 295 $ | 31/03/2024 |
Postes actifs de Lawrence Kenyon
| Sociétés | Poste | Début |
|---|---|---|
| OUTLOOK THERAPEUTICS, INC. | Director of Finance/CFO | 18/06/2018 |
Anciens postes connus de Lawrence Kenyon
| Sociétés | Poste | Fin |
|---|---|---|
| ARNO THERAPEUTICS, INC. | Director of Finance/CFO | 01/09/2015 |
Tamir Biotechnology, Inc.
 Tamir Biotechnology, Inc. Medical SpecialtiesHealth Technology Tamir Biotechnology, Inc. engages in the discovering and developing of new class therapeutic drugs for the treatment of cancer and other pathological conditions. The firm's proprietary drug discovery program is also the basis for the development of recombinant designed RNases for chemical conjugation and fusion products with various targeting moieties, such as monoclonal antibodies, growth factors, and cytokines. The company was founded on August 24, 1981 and is headquartered in Short Hills, NJ. | Chief Executive Officer | 31/03/2013 |
Par Pharmaceutical, Inc.
 Par Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Par Pharmaceutical, Inc. manufactures and markets generic drugs and pharmaceuticals products. It produces drugs for hypertension, inflammation, depression and pain. The firm distributes its products in the semi-solid form of a cream. The company was founded in 1978 and is headquartered in Chestnut Ridge, NY. | Director of Finance/CFO | 01/07/2010 |
| PAR PHARMACEUTICAL COMPANIES, INC. | Director of Finance/CFO | 04/06/2010 |
Tamir Biotechnology, Inc.
Tamir Biotechnology, Inc. Medical SpecialtiesHealth Technology Tamir Biotechnology, Inc. engages in the discovering and developing of new class therapeutic drugs for the treatment of cancer and other pathological conditions. The firm's proprietary drug discovery program is also the basis for the development of recombinant designed RNases for chemical conjugation and fusion products with various targeting moieties, such as monoclonal antibodies, growth factors, and cytokines. The company was founded on August 24, 1981 and is headquartered in Short Hills, NJ. | Director of Finance/CFO | 01/02/2009 |
Formation de Lawrence Kenyon
| University of Wisconsin | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ARNO THERAPEUTICS, INC. | Health Technology |
| OUTLOOK THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Tamir Biotechnology, Inc.
Tamir Biotechnology, Inc. Medical SpecialtiesHealth Technology Tamir Biotechnology, Inc. engages in the discovering and developing of new class therapeutic drugs for the treatment of cancer and other pathological conditions. The firm's proprietary drug discovery program is also the basis for the development of recombinant designed RNases for chemical conjugation and fusion products with various targeting moieties, such as monoclonal antibodies, growth factors, and cytokines. The company was founded on August 24, 1981 and is headquartered in Short Hills, NJ. | Health Technology |
Endo Generics Holdings, Inc.
 Endo Generics Holdings, Inc. Pharmaceuticals: GenericHealth Technology Endo Generics Holdings, Inc. develops, manufactures, and markets generic pharmaceutical products. It also offers dosage, branded, and generic sterile injectable products. The company was founded in 1978 and is headquartered in New York, NY. | Health Technology |
NeoPharm, Inc.
 NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | Health Technology |
Par Pharmaceutical, Inc.
Par Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Par Pharmaceutical, Inc. manufactures and markets generic drugs and pharmaceuticals products. It produces drugs for hypertension, inflammation, depression and pain. The firm distributes its products in the semi-solid form of a cream. The company was founded in 1978 and is headquartered in Chestnut Ridge, NY. | Health Technology |
